logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2019
MacroGenics Inc.
Submisson of BLA for Margetuximab
HER2-positive metastatic breast cancer
2H 2019
INmune Bio Inc.
Initial data from phase I portion of phase I/II study of INKmune
Relapse refractory ovarian cancer in women
Q3 2019
Aravive, Inc.
Interim safety, pharmacodynamic, and pharmacokinetic data for Phase 1b portion of Phase 1b/2 clinical trial of AVB-S6-500
Platinum-resistant recurrent ovarian cancer
Q3 2019
DBV Technologies S.A. -
Resubmission of BLA for Viaskin Peanut
Peanut allergy
Jul 2019
BioPharmX Corp
Top-line data from phase IIb clinical trial of BPX-041
Papulopustular rosacea
2H 2019
Syndax Pharma
Initial results from phase I dose escalation trial of SNDX-6352
Chronic graft versus host disease (cGVHD)
2H 2019
Supernus Pharmaceuticals, Inc.
Submission of NDA for SPN-812
Attention-Deficit-Hyperactivity Disorder
2H 2019
Unum Therapeutics Inc.
Additional data from phase I trial of ACTR087 in combination with SEA-BCMA (ATTCK-17-01)
Relapsed or refractory Multiple Myeloma
2H 2019
G1 Therapeutics, Inc.
Additional data from phase Ib clinical trial of Lerociclib/Faslodex
ER+, HER2- breast cancer
2H 2019
G1 Therapeutics, Inc.
Preliminary dose-escalation data from phase Ib clinical trial of Lerociclib/Tagrisso
Non-small cell lung cancer
2H 2019
G1 Therapeutics, Inc.
Preliminary dose-escalation data from phase I clinical trial of G1T48
ER+ breast cancer
2H 2019
Aldeyra Therapeutics, Inc.
Results from phase III clinical trial of 0.5% topical ocular Reproxalap(SOLACE)
Noninfectious anterior uveitis
2H 2019
Aldeyra Therapeutics, Inc.
Results from Part 1 of a phase III clinical trial of 1% topical dermal Reproxalap(RESET)
Ichthyosis associated with Sjögren-Larsson Syndrome
2H 2019
Replimune Group Inc.
Data from full Phase 1 part of Phase 1/2 study of RP1
solid tumors
2H 2019
Replimune Group Inc.
Data from full Phase 1 part of Phase 1/2 study of RP1 combined with Opdivo
solid tumors
2H 2019
Constellation Pharmaceuticals, Inc.
Interim phase II data of CPI-1205 (ProSTAR)
Metastatic castration-resistant prostate cancer (mCRPC)
2H 2019
TCR2 Therapeutics
Clinical data from phase 1/2 clinical trial of TC-210
Mesothelin-positive solid tumors
2H 2019
TCR2 Therapeutics
Filing of IND for TC-110
Ovarian cancer
Jul 2019
Neon Therapeutics, Inc.
Top-line clinical results from phase Ib trial of NEO-PV-01 and Opdivo
Metastatic or advanced melanoma, lung, or bladder cancer
2H 2019
Molecular Templates Inc.
Update from phase II study of MT-3724
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
2H 2019
Molecular Templates Inc.
Update from Phase II study of MT-3724 in combination chemotherapy (GemOx)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
2H 2019
Molecular Templates Inc.
Update from Phase II study of MT-3724 in combination with Revlimid
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Q3 2019
Molecular Templates Inc.
Update from phase I study of MT-5111
Relapsed/refractory patients with HER2-positive solid tumors
2H 2019
Allena Pharmaceuticals, Inc.
Topline data from phase III program of Reloxaliase (URIROX-1)
Enteric hyperoxaluria
2H 2019
Verrica Pharmaceuticals Inc.
Submission of NDA for VP-102
Molluscum contagiosum